Editorial: early post‐induction anti‐TNF drug monitoring can predict long‐term therapeutic outcomes in inflammatory bowel disease

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|47|3|436-437

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.3, 2018-02, pp. : 436-437

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Undetectable anti‐TNF drug levels in patients with long‐term remission predict successful drug withdrawal

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 3, 2015-08 ,pp. : 356-364

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of anti‐TNF therapy in elderly patients with inflammatory bowel disease

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 4, 2015-08 ,pp. : 441-451

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: therapeutic drug monitoring and inflammatory bowel disease—a call for an urgent standardization of the results

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 3, 2018-02 ,pp. : 448-449

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failed

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 7, 2015-04 ,pp. : 613-623

John Wiley & Sons Inc

Access to resources Recommend Favorite

Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors

By  

INTERNAL MEDICINE JOURNAL, Vol. 45, Iss. 11, 2015-11 ,pp. : 1154-1160

John Wiley & Sons Inc

Access to resources Recommend Favorite